Stock 300436 FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Fujian Cosunter Pharmaceutical Co., Ltd.

Equities

300436

CNE100001YZ0

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
17.94 CNY +2.22% Intraday chart for Fujian Cosunter Pharmaceutical Co., Ltd. +4.85% -30.00%
Apr. 19 Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Jiangsu Zhongxing Pharm Co., Ltd. cancelled the transaction announced on July 5, 2021 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 3,424 4,663 5,410 7,626 6,237 4,082
Enterprise Value (EV) 1 3,396 4,715 5,501 7,420 6,309 4,338
P/E ratio 202 x 416 x 366 x -206 x -48.9 x -11.7 x
Yield - - - - - -
Capitalization / Revenue 8.51 x 11.2 x 14.7 x 20.6 x 16.2 x 9.66 x
EV / Revenue 8.44 x 11.4 x 14.9 x 20 x 16.4 x 10.3 x
EV / EBITDA 143 x 207 x 151 x -251 x -35.8 x -35.3 x
EV / FCF -13.6 x -61.3 x -641 x -34.1 x -23.6 x -20.5 x
FCF Yield -7.37% -1.63% -0.16% -2.93% -4.23% -4.87%
Price to Book 6.13 x 8.25 x 9.38 x 7.31 x 6.72 x 7.9 x
Nbr of stocks (in thousands) 141,211 140,000 140,000 158,777 159,267 159,267
Reference price 2 24.25 33.31 38.64 48.03 39.16 25.63
Announcement Date 4/1/19 3/25/20 3/31/21 4/21/22 4/20/23 4/19/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 402.4 414.9 368.5 370.4 385.8 422.7
EBITDA 1 23.79 22.81 36.4 -29.58 -176.1 -122.7
EBIT 1 1.461 0.9361 -0.6712 -81.17 -234.3 -194.6
Operating Margin 0.36% 0.23% -0.18% -21.91% -60.73% -46.02%
Earnings before Tax (EBT) 1 11.76 12.15 15.35 -45.69 -163.4 -298
Net income 1 16.48 10.74 14.82 -34.89 -127.4 -348.6
Net margin 4.1% 2.59% 4.02% -9.42% -33.03% -82.46%
EPS 2 0.1200 0.0800 0.1056 -0.2335 -0.8004 -2.189
Free Cash Flow 1 -250.4 -76.92 -8.581 -217.3 -267.1 -211.3
FCF margin -62.22% -18.54% -2.33% -58.65% -69.24% -49.99%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/1/19 3/25/20 3/31/21 4/21/22 4/20/23 4/19/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 51.9 91.6 - 72.6 256
Net Cash position 1 27.9 - - 206 - -
Leverage (Debt/EBITDA) - 2.277 x 2.516 x - -0.4121 x -2.089 x
Free Cash Flow 1 -250 -76.9 -8.58 -217 -267 -211
ROE (net income / shareholders' equity) 3% 2.21% 2.86% -4.19% -14% -49.2%
ROA (Net income/ Total Assets) 0.11% 0.07% -0.04% -4.14% -9.96% -7.82%
Assets 1 14,372 16,081 -33,616 843.3 1,280 4,457
Book Value Per Share 2 3.960 4.040 4.120 6.570 5.830 3.240
Cash Flow per Share 2 0.6100 0.6700 0.9700 2.480 1.500 1.270
Capex 1 229 67.8 54.5 174 196 201
Capex / Sales 56.97% 16.35% 14.78% 47.08% 50.8% 47.61%
Announcement Date 4/1/19 3/25/20 3/31/21 4/21/22 4/20/23 4/19/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. Stock Fujian Cosunter Pharmaceutical Co., Ltd.
-30.00% 395M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.83% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.91% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.24% 325B
ABBVIE INC. Stock AbbVie Inc.
+5.90% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 235B
NOVARTIS AG Stock Novartis AG
+3.65% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.94% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300436 Stock
  4. Financials Fujian Cosunter Pharmaceutical Co., Ltd.